Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. Nuclear & Precision Health Solutions has 40+ years of expertise and is a national source for both SPECT and PET radiopharmaceuticals, operating the largest network of 130 pharmacies, 30+ cyclotron facilities, and the only Alpha contract manufacturing site in the United States.
ITM, a radiopharmaceutical biotech company, is dedicated to providing the most precise cancer radiotherapeutics and diagnostics to meet the needs of patients, clinicians and our partners through excellence in development, production and global supply. With patient benefit as the driving principle for all we do, ITM is advancing a broad pipeline combining its superior radioisotopes with targeting molecules to create precision oncology treatments. ITM is leveraging its leadership and nearly two decades of radiopharma expertise combined with its worldwide network to enable nuclear medicine to reach its full potential for helping patients live longer and better.
Oncodesign is a biopharmaceutical company dedicated to precision medicine. With its unique experience acquired by working with more than 800 clients along with its comprehensive technological platform combining state-of-the-art medicinal chemistry, pharmacology, bioanalysis, pharmaco-imaging & artificial intelligence, Oncodesign orients, drives & executes the development of drug candidates from hit findings up to early clinical phases. Oncodesign has specialties in imaging and targeted radiotherapies.
Our expertise & capacities enable to provide imaging solutions to monitor your drug in order to better predict its efficacy. Our multimodal imaging platforms are an open door for non-invasive techniques to understand the pharmacology of your compound in less than 6 months. Finally, we have a unique offering dedicated to pre-clinical evaluation of TRT: a unique combination of our skills in radiochemistry and in vivo pharmaco-imaging in order to assess systemic radiotherapy efficacy.
ABX-CRO is an independent international CRO with more than 20 years of experience in radiooncology, dosimetry, and molecular radiotherapy. ABX-CRO offers product development services from non-clinical through Phase-0 microdosing to global Phase III studies. Highly specialised radiooncology trials require close multidisciplinary interaction of pharmacists, physicists, clinicians and statisticians, as well as clinical trial experts all the way through from study design and conduct to final statistical analysis. Reflecting this, ABX-CRO comprehensively integrates scientific, medical and clinical trial management expertise required for advanced imaging and therapeutic trials. We closely cooperate with key opinion leaders, research institutes and universities worldwide to realise non-clinical studies for novel IMPs and to ensure recruitment and adequate treatment facilities for a wide range of indications.
Located near Aix-en-Provence, in France, PMB is a 160-employee SMB. With a strong expertise in brazing, the company designs and manufactures complex mechanical assemblies and components (ceramic-metal, radio-frequency…), linear particle accelerators and cyclotrons. PMB is part of the French industrial group ALCEN.
PMB has developed a cutting-edge, automated radiopharmaceutical production system for PET imaging, combining a cyclotron with a robotized radiochemistry room. Our GMP-compliant R&D iMiLAB synthesizer allows the development of various radiopharmaceuticals using microfluidic cassettes. It can also be used for the production of single doses or small batches.
FIELD-LAB - NRG
IONETIX is a US-based cyclotron technology company founded in 2009 as an end-to-end radiopharmaceutical solution provider. As a leading manufacturer of diagnostic radionuclide imaging agents, IONETIX is now applying their cyclotron technology and expertise on Targeted Alpha Therapy focusing on isotope production, drug manufacturing and distribution of alpha radionuclides, including Ac-225 and At-211.
Curium is the world’s largest nuclear medicine company with more than a century of industry experience. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.
With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name ‘Curium’ honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. The tagline ‘Life Forward’ represents our commitment to securing a brighter future for all those we serve: An enhanced quality of care for our patients. A trusted partner to our customers. A supportive employer to our valued team.
Chelatec was founded in 2000 by seasoned scientists trained in the development of radiopharmaceuticals. Experts in the use of radioactive tracers, they decided to offer their knowledge in preclinical development of targeted radiotherapeutics to pharma and biotech.
With state-of-the-art fully equipped laboratories for radiolabeling, radioanalyses, handling of cells and housing of animals, Chelatec is recognized for its reliable expertise and offers a unique combination of custom radiolabeling, in vitro assays and in vivo investigations capabilities.
Specializing in radiopharmaceutical R&D, Chelatec will provide you with information on your Investigational Medicinal Product to be part of the documentation package. All quality and non-clinical safety data required for translation of a radiopharmaceutical.
Our services cover/include:
- Radioactive labeling
- Analytical controls (HPLC, iTLC/TLC, SDS-PAGE...)
- Stability studies (storage stability, plasma stability)
- In vitro assays
(Binding affinity, IRF, internalization, cytotoxicity, autoradiography on tissue sections)
- In vivo investigations
(Pharmacokinetics, biodistribution, efficacy, preclinical dosimetry)
SpectronRx provides therapeutic and diagnostic isotopes for clinical and research use - including theranostics, molecular radiotherapies and custom manufacturing. We are your curative supplier, specializing in providing you flexible and efficient contract manufacturing services. As a resource in the market, SpectronRx is an approved FDA manufacturer of radioactive drugs with many years of experience in custom manufacturing for major global research organizations and institutions. Our credo is built around our high-caliber of quality - we pride ourselves in our state-of-the-art manufacturing facilities and exemplary staff credentials, which provide you the highest level of "white-glove" service in the industry.
Founded in 2005 as a spin-off of the Institut de Chimie Moléculaire de l’Univerisité de Bourgogne, CheMatech is a unique company in Europe specialized in the design and production of chelators (DOTA, NOTA derivtaives) for Nuclear Medicine and Molecular Imaging. These molecules are used for the radiolabeling of biovectors such as peptides or antibodies. CheMatech provides its clients with a catalog of chelators suitable for most radiometals used for PET, SPECT or therapy and also offers custom syntheses, from the design of the chelator to the production in bulk. CheMatech is able to produce GMP chelators, and related molecules, for the production of APIs from gram to kilogram scale. CheMatech constantly innovates and offers new solutions thanks to internal R&D activity and joint research programs with internationally recognized research teams.
Based in Dijon, France, CheMatech’s facilities include 500 m2 of laboratories with a separate GMP area. With 1300 clients all over the world, the company is present in more than 30 countries.
Trasis was founded in 2004 by Gauthier Philippart and Jean-Luc Morelle, the designers of the first radio-synthesizers to combine high-yield synthesis and GMP.
They put together their expertise and their knowledge of the radiopharmaceutical industry and founded Trasis, an innovative and forward-looking company. Trasis has now a track record in developing instruments and methods recognized throughout the world.
At Trasis we are dedicated to helping the medical community access new radio-labeled therapeutic and diagnostic substances easily and faster. To this end, we design, manufacture, sell and support high-performance synthesizers, dose preparation equipment, their shielding, and accessories. We also develop customized synthetic methods and instruments. We can provide GMP Active Pharmaceutical Ingredients (API) and assist our customers with their regulatory affairs.
Our proven radiopharmaceutical expertise, coupled with our high-end instruments allow us to provide fully integrated solutions for effective tracer production and faster transition from drug development to marketing authorization.
Our equipment is used worldwide in nuclear medicine departments, research centers, radiopharmaceutical production facilities, and pharmaceutical companies.